Invasive aspergillosis in severely immunosuppressed patients: Significant progress, but many unresolved problems

Transplant Infectious Disease

Volumn 10, Issue 3, 2008, Pages 151-155

  Maschmeyer, G ^a  

^a KLINIKUM ERNST VON BERGMANN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; GALACTOMANNAN; IMMUNOSUPPRESSIVE AGENT; POSACONAZOLE; TUMOR NECROSIS FACTOR ANTIBODY; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASPERGILLOSIS; ASPERGILLUS; BRONCHOSCOPY; CHEMOPROPHYLAXIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISTRIBUTION VOLUME; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EARLY DIAGNOSIS; EARLY INTERVENTION; EDITORIAL; FUNGUS SPORE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; INVASIVE PROCEDURE; LUNG ASPERGILLOSIS; LUNG INFILTRATE; MORBIDITY; MORTALITY; NEEDLE BIOPSY; OPEN LUNG BIOPSY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; SURVIVAL; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; LEUKEMIA, MYELOID, ACUTE;

EID: 43949091474     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2008.00308.x     Document Type: Editorial

References (48)

1. Jantunen E, Nihtinen A, Anttila VJ. Changing landscape of invasive aspergillosis in allogeneic stem cell transplant recipients. Transpl Infect Dis 2008 10 : 156 161.
2. Mihu CN, King E, Yossepovitch O, et al. Risk factors and attributable mortality of late aspergillosis after T-cell depleted hematopoietic stem cell transplantation. Transpl Infect Dis 2008 10 : 162 167.
3. Ho KM, Duff O, Chambers D, Murray R. Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals. Transpl Infect Dis 2008 10 : 168 176.
4. Crassard N, Hadden H, Pondarré C, et al. Invasive aspergillosis and allogeneic hematopoetic stem cell transplantation in children: a 15-year experience. Transpl Infect Dis 2008 10 : 177 183.
5. Eschertzhuber S, Velik-Salchner C, Hoermann C, Hoefer D, Lass-Florl C. Caspofungin-resistant Aspergillus flavus after heart transplantation and mechanical circulatory support: a case report. Transpl Infect Dis 2008 10 : 190 192.
6. Gonzalez-Vicent M, Diaz MA, Comenero I, Sevilla J, Madero L. Primary intestinal aspergillosis after autologous peripheral blood progenitor cell transplantation: an unusual presentation of invasive aspergillosis. Transpl Infect Dis 2008 10 : 193 196.
7. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998 26 : 781 803.
8. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001 32 : 358 366.
9. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000 79 : 250 260.
10. Maschmeyer G, Beinert T, et al. and Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003 82 (Suppl 2) : S118 S126.
11. Herbrecht R, Denning DW, et al. and Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 347 : 408 415.
12. Cornely OA, Maertens J, et al. and AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007 44 : 1289 1297.
13. Maertens J, Raad I, et al. and Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004 39 : 1563 1571.
14. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007 44 : 2 12.
15. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007 356 : 348 359.
16. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007 356 : 335 347.
17. Cornely OA, Böhme A, Reichert D, et al. On behalf of the Multinational Case Registry of the Infectious Diseases Working Party of the German Society for Hematology and Oncology. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother 2008 61 : 939 946.
18. de Fabritiis P, Spagnoli A, Di Bartolomeo P, et al. Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant 2007 40 : 245 249.
19. Allinson K, Kolve H, Gumbinger HG, Vormoor HJ, Ehlert K, Groll AH. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother 2008 61 : 734 742.
20. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007 44 : 373 379.
21. Maschmeyer G. Pneumonia in febrile neutropenic patients: radiologic diagnosis. Curr Opin Oncol 2001 13 : 229 235.
22. Lass-Flörl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007 45 : e101 e104.
23. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004 190 : 641 649.
24. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001 97 : 1604 1610.
25. Weisser M, Rausch C, Droll A, et al. Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies. Clin Infect Dis 2005 41 : 1143 1149.
26. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006 42 : 1417 1427.
27. Buchheidt D, Hummel M, Schleiermacher D, et al. Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004 125 : 196 202.
28. Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis 2006 42 : 487 489.
29. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005 41 : 654 659.
30. Schwartz S, Ruhnke M, Ribaud P, Reed E, Troke P Thiel E. Poor efficacy of amphotericin B-based therapy in CNS aspergillosis. Mycoses 2007 50 : 196 200.
31. Viscoli C, Herbrecht R, Akan H, et al. Caspofungin as first-line therapy of invasive aspergillosis in haematological patients: a study of the EORTC Infectious Diseases Group. J Chemother 2007 19 (Suppl 3) : 36 (TIMM-3 abstr # O.12).
32. Maschmeyer G, Haas A. Defining clinical failure for salvage studies. Med Mycol 2006 44 : S315 S318.
33. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001 19 : 253 259.
34. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007 109 : 1532 1535.
35. Hospenthal DR, Kwon-Chung KJ, Bennett JE. Concentrations of airborne Aspergillus compared to the incidence of invasive aspergillosis: lack of correlation. Med Mycol 1998 36 : 165 168.
36. Pini G, Donato R, Faggi E, Fanci R. Two years of a fungal aerobiocontamination survey in a Florentine haematology ward. Eur J Epidemiol 2004 19 : 693 698.
37. Raad I, Hanna H, Osting C, et al. Masking of neutropenic patients on transport from hospital rooms is associated with a decrease in nosocomial aspergillosis during construction. Infect Control Hosp Epidemiol 2002 23 : 41 43.
38. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997 175 : 1459 1466.
39. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006 91 : 986 989.
40. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006 91 : 1068 1075.
41. Pulte D, Gondos A, Brenner H. Major improvements in survival in hematologic malignancies in the early 2000s. Blood 2007 110 : 195a.
42. Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006 132 : 3 12.
43. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004 38 : 1261 1265 (Correction Clin Infect Dis 2004; 39:1254-1255).
44. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005 191 : 1350 1360.
45. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007 39 : 425 429.
46. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005 41 : 60 66.
47. Rickerts V, Just-Nübling G, Konrad F, et al. Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. Eur J Clin Microbiol Infect Dis 2006 25 : 8 13.
48. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007 356 : 1481 1483.